Ovarian Cancer

Researchers further evaluate OvaRex Mab for ovarian cancer

Published in Women's Health Weekly, March 17th, 2005

Researchers at clinical centers in Virginia are further evaluating OvaRex MAb (oregovomab), an investigational therapy, to determine the extent of remission in ovarian cancer patients who have a favorable response to surgery and chemotherapy.

For the majority of patients with advanced ovarian cancer, the current standard of care and front-line treatments - surgery and chemotherapy - are not enough to control the high recurrence rate.

They are also assessing survival, quality of life, immune response, and safety. Women with stage III or IV ovarian cancer, who qualify to participate in the ongoing clinical research, must begin taking the study...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2005-03-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry